07:00 , Aug 21, 2014 |  BC Innovations  |  Cover Story

Fat chance for cancer cachexia

With no drugs on the market and a pair of recent Phase III failures in cancer-associated cachexia, companies could be better off turning to the cause of the wasting disease rather than targeting its symptoms....
08:00 , Dec 10, 2012 |  BC Week In Review  |  Financial News

Akela Pharma financial update

Akela voluntarily delisted its shares from the Toronto Stock Exchange. Akela, which will not be actively listed on a market, said the decision is due to its inability to meet the listing requirements. Akela Pharma...
07:00 , Mar 22, 2012 |  BC Innovations  |  Cover Story

Bioartificial pancreas beta test

Beta-O2 Technologies Ltd. and an international team of academic collaborators have shown that the company's bioartificial pancreas can house donor islets, supply them with oxygen and protect them from the host immune system in vivo...
07:00 , Oct 21, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Dermatology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Dermatology Wounds Growth hormone-releasing hormone (GHRH); GHRH receptor (GHRHR) Mouse studies suggest that GHRHR agonists could help treat...
07:00 , Mar 10, 2008 |  BC Week In Review  |  Clinical News

EDACS: Phase I started

Akela began an open-label, single-dose, Asian Phase I trial to compare 3 extended-release formulations of an undisclosed opioid with an immediate-release formulation of the same opioid in 12 healthy volunteers. Akela Pharma Inc. (TSX:AKL), St....
08:00 , Feb 11, 2008 |  BC Week In Review  |  Clinical News

Fentanyl Taifun: Phase III delayed

Akela delayed the start of a U.S. Phase III trial of Fentanyl Taifun from next quarter after being notified by FDA that its preclinical inhalation toxicology studies were deemed invalid due to good laboratory practice...
08:00 , Jan 7, 2008 |  BC Week In Review  |  Company News

Akela Pharma, J&J deal

The companies expanded the territory of a June 2007 deal for Akela's Fentanyl Taifun to include Canada. The original deal gave Johnson & Johnson's Janssen Pharmaceutica N.V. subsidiary exclusive rights to the inhalable fentanyl...
07:00 , Sep 10, 2007 |  BC Week In Review  |  Clinical News

Fentanyl Taifun: Phase III start

This year, AKL plans to start a Phase III trial in about 400 patients. Akela Pharma Inc. (TSX:AKL; FSE:LD9), St. Laurent, Quebec   Product: Fentanyl Taifun   Business: Neurology   Molecular target: Mu opioid receptor   Description:...
07:00 , Sep 10, 2007 |  BC Week In Review  |  Clinical News

Fentanyl Taifun: Phase IIb data

In a 50-patient, double-blind extension of an international Phase IIb trial, Fentanyl Taifun met the primary endpoint of a median time to significant pain relief that was significantly faster than placebo (5.2 min vs. 7...
07:00 , Sep 3, 2007 |  BC Week In Review  |  Clinical News

LAB calcitonin gene related peptide: Phase IIb started

AKL began a Phase IIb study in 16 patients to compare 5 mg of inhaled CGRP vs. placebo. Akela Pharma Inc. (TSX:AKL; FSE:LD9), St. Laurent, Quebec   Product: LAB calcitonin gene related peptide (CGRP)   Business: Inflammation...